The Mission

 

Stream Biomedical was founded to address unmet therapeutic needs for individuals suffering as a result of neurologic trauma and/or degeneration. The goal is to save brain and associated function from potentially debilitating outcomes... to best preserve what makes us who we are.

Company Overview

Stream Biomedical is commercializing a therapeutic protein which has been shown to be significantly neuroprotective and neuroreparative, resulting in dramatic functional improvement when administered after neurologic insult. The initial target therapeutic application is for the treatment of acute stroke. Later targets include traumatic brain injury (TBI) and Alzheimer's/dementia.

The Unmet Need

800000

Strokes/ year

in the United States of America
15000000

Strokes/ year

Worldwide

Only 10% of Survivors return to normal activity. Stroke is the most debilitating condition on the planet.

Our Solution

Recombinant Human (rh) Perlecan Domain V (DV)


stroke therapy

DV is actively generated in response to vigorous activity, traumatic brain injury (TBI) & stroke.


DV is a critical component of the body’s post-stroke attempt at self-repair.


rhDV has proven preclinically to be neuroprotective; in other words, rhDV protects neurons (fundamental cells of the brain) and limits the effects of injury or degeneration once administered.


rhDV has also been shown to support neurologic repair in vivo; it is both angiogenic (helps create new intracranial blood vessels) and neurogenic (helps proliferate new “baby” neurons in the brain and fosters them to become functional “adult” neurons)


Most importantly, rhDV has shown to provide full post-acute-stroke functional recovery in vivo stroke models